Cytogenetic, molecular and functional analysis has shown that chromosome region 6q27 harbors a senescence inducing gene and a tumor suppressor gene involved in several solid and hematologic malignancies. We have cloned at 6q27 and characterized the RNASE6PL gene which belongs to a family of cytoplasmic RNases highly conserved from plants, to man. Analysis of 55 primary ovarian tumors and several ovarian tumor cell lines indicated that the RNASE6PL gene is not mutated in tumor tissues, but its expression is signi®cantly reduced in 30% of primary ovarian tumors and in 75% of ovarian tumor cell lines. The promoter region of the gene was unaected in tumors cell lines. Transfection of RNASE6PL cDNA into HEY4 and SG10G ovarian tumor cell lines suppressed tumorigenicity in nude mice. When tumors were induced by RNASE6PL-transfected cells, they completely lacked expression of RNASE6PL cDNA. Tumorigenicity was suppressed also in RNASE6PL-transfected pRPcT1/ H6cl2T cells, derived from a human/mouse monochromosomic hybrid carrying a human chromosome 6 deleted at 6q27. Moreover, 63.6% of HEY4 clones and 42.8% of the clones of XP12ROSV, a Xeroderma pigmentosum
Introduction
Abnormalities of the long arm of chromosome 6 are associated with several solid neoplasms including carcinomas of the ovary (Saito et al., 1992; Foulkes et al., 1993; Cooke et al., 1996; Orphanos et al., 1995; Tibiletti et al., 1996) , breast (Develee et al., 1991; Theile et al., 1996; Chappel et al., 1997) , uterus (Tibiletti et al., 1997) , stomach (Queimado et al., 1995) , liver (DeSouza et al., 1995) , colon and rectum (Honchel et al., 1996) , kidney (Morita et al., 1991) , parathyroid gland (Tahara et al., 1996) , melanoma (Millikin et al., 1991) and hematological malignancies such as non-Hodgkin B-cell lymphoma (Gaidano et al., 1992) and acute lymphoblastic leukemia (Hayashi et al., 1990) . Among the solid tumors, ovarian cancers have been the focus of intense studies, because very little is known about the genetic pathways underlying ovarian carcinogenesis. Moreover, ovarian tumors are still associated with a rather high mortality rate, mostly due to delay in diagnosis which usually is performed at the late stages of the disease. The elucidation of the genetic events leading to inactivation of tumor suppressor genes or activation of oncogenes in ovarian tumors is therefore greatly needed.
By employing the loss of heterozygosity (LOH) assay with markers localized along the entire long arm of chromosome 6, several consensus regions of loss have been delineated. From centromere to telomere the order of these regions is 6q21 ± 23.3 (Orphanos et al., 1995; Shridhar et al., 1999) , 6q25.1 ± 25.2 and 6q26 ± 27 (Saito et al., 1992; Foulkes et al., 1993; Cooke et al., 1996; Orphanos et al., 1995; Tibiletti et al., 1996) . The latter region has been deeply investigated and ®ne mapping has disclosed a genomic interval¯anked by markers D6S193 and D6S149 as the shortest region lost in ovarian tumors (Cooke et al., 1996; Saito et al., 1996) . Deletions at 6q27 were detected in 18 out of 20 benign ovarian tumors Oncogene (2001) (Tibiletti et al., 1998) , indicating that alterations in one or more genes mapping in this region are one of the earliest events in ovarian carcinogenesis.
Furthermore, the survey of more than 12 studies, reporting allele losses in ovarian carcinomas, allowed the identi®cation of an even shorter region, de®ned by markers D6S193 and D6S297 which is included in the greater D6S193 ± D6S149 interval (Cooke et al., 1996) . The analysis of the critical D6S193 ± D6S149 interval resulted in the construction of a long range physical map and a YAC contig of the region (Tibiletti et al., 1998; Hauptschein et al., 1998) . Physical measurements indicate that the distance between D6S193 and D6S149 is approximately 900 Kb, whereas the smaller D6S193 ± D6S297 interval spans about 100 Kb (Tibiletti et al., 1998; Hauptschein et al., 1998) . Within the latter genomic region we have recently mapped, cloned and characterized a cDNA (RNASE6PL) Acquati et al., 2000) coding for a protein with a great similarity to a class of highly conserved cytoplasmic RNases present in plants (Anderson et al., 1986; Clark et al., 1990) , animal viruses (Schneider et al., 1993) , bacteria (Meador and Kennell, 1990) , fungi (McClure et al., 1989) , drosophila (Hime et al., 1995) and mouse . Interestingly, although these enzymes from dierent organisms ful®ll dierent biological functions, a common feature of their activity is the control of cell growth (McClure et al., 1990 ). This eect is particularly challenging due to the chromosomal location of the human RNASE6PL gene at 6q27. Indeed, RNASE6PL may be a candidate tumor suppressor gene whose loss could contribute to the development or progression of ovarian cancers. We have assessed such potential role for RNASE6PL and we present here molecular and functional data supporting an involvement of this gene in senescence and in ovarian tumorigenesis.
Results

Genomic organization of the RNASE6PL gene
The structure of the RNASE6PL gene was determined by YAC subcloning (Tibiletti et al., 1998 , Hauptschein et al., 1998 and cosmid assembling. This gene, which is present in a single copy in the genome, spans approximately 27 Kb of genomic DNA and is split into nine exons and eight introns (the accession number for the genomic sequence of the gene is AL159163).
Mutation analysis of the RNASE6PL gene in primary ovarian cancers
Fifty-®ve microdissected primary ovarian tumors, classi®ed from stage II to stage IV, were selected for this analysis. These tumors were already known to contain 6q26-qter deletions in at least one of the chromosome 6 homologues (Tibiletti et al., 1996; Tibiletti and Taramelli, unpublished results) . According to the Knudson hypothesis, the remaining RNASE6PL allele or alleles (most of the tumors were aneuploid for chromosome 6) are expected to be altered by inactivating mutations or small deletions. Using exon 1, 2, 7, 8 and 9 primer pairs, several abnormal SSCP bands were observed. Sequence analysis revealed the presence of a missense common variant in exon 9 (a C to T at nucleotide position 708 with respect to the ATG replacing Arg with Trip). In addition, three silent base substitutions in exon 1, 8 and 9 and two common single-base changes in intron 1 and 6 were detected. It was possible to con®rm the germline origin only of exon 9 and intron 1 modi®cations. Most likely these sequence variants are common polymorphisms because, at least in some cases, the same alterations were found to be present in the corresponding germ line. Also, the 5' and 3' regions of the gene, investigated by sequence analysis for the extension of 2 Kb, were found to be intact. On the whole, this analysis indicates that the RNASE6PL gene is not aected by mutations in primary ovarian cancers. Furthermore, the HEY4 and OVCAR3 ovarian cancer cell lines were also investigated, but as in the primary tumors no mutations were found.
Expression of RNASE6PL in normal tissues, primary ovarian tumors and ovarian tumor cell lines
Since the RNASE6PL gene does not seem to be mutated in primary ovarian tumors and tumor cell lines, we proceeded to study its expression in normal and neoplastic tissues. The 1.4 Kb message of the RNASE6PL gene is rather ubiquitous being present, although at variable levels, in all tissues that were examined ( Figure 1a) . When fourteen ovarian cell lines were studied and compared with normal ovarian tissue, several changes in RNASE6PL expression were detected. Figure 1b shows a representative example of eight cell lines where a reduced signal of RNASE6PL mRNA was detected in ®ve samples (HEY4, OV1225, OV166, SW626, OVRS1000), while in one cell line (SG10G) the expression of the gene was totally abolished and in two cell lines (SKOV3 and OVCR3) was greatly enhanced. A series of 55 primary ovarian tumors were also analysed and decreased expression of RNASE6PL mRNA, below 25% of the normal ovarian tissue, was detected in 15 (30%) of them. As shown in Figure 1c , some samples displayed easily detectable levels of RNASE6PL mRNA, whereas in other samples the signal was barely detectable.
Transfection of tumor and immortal cell lines, induction of senescence and suppression of tumorigenicity In order to verify whether the RNASE6PL gene suppresses in vitro the transformed and immortal phenotype, we transfected the ovarian cancer cell lines HEY4 and SG10G as well as the SV40-immortalized cell line XP12ROSV with the pcDNA/Neo-RNS6 vector, containing the full-length human RNASE6PL cDNA under the control of the cytomegalovirus immediate-early promoter. Suppression of tumorigeniOncogene Tumor suppressor and senescence-inducing gene at 6q27 F Acquati et al city was assessed in nude mice by inoculation of transfected HEY4 and SG10G cells as well as by inoculation of pRPc cells cotransfected with the plasmids pMT89, containing the RNASE6PL cDNA, and pGK (see Materials and methods). These cell lines were selected for transfection for the following reasons: the HEY4 cells show an expression of RNASE6PL reduced to 10% of normal ovarian tissue (Figure 1b) , while the SG10G and XP12ROSV cells completely lack expression of the RNASE6PL gene. The SG10G cell line was found to miss completely chromosome 6 as evidenced by conventional cytogenetic and FISH analyses (data not shown). The pRPc cells are mouse cells derived from a tumor induced in nude mice by the human/mouse monochromosomic hybrid pRPcT1/H6 and harbor a human chromosome 6 deleted at 6q27 (Gualandri et al., 1994). Table 1 shows a summary of the results of transfection of the RNASE6PL cDNA into pRPc, HEY4, SG10G and XP12ROSV cells. Some characteristics of the results were common among the transfected cell lines. In fact, the number of living clones that could be propagated in culture, compared to the number of clones picked up after selection, was constantly lower in cells transfected with the RNA-SE6PL cDNA inserted in sense orientation (S) than in cells transfected with the RNASE6PL cDNA inserted in antisense orientation (AS) or with the vector alone, suggesting that the RNASE6PL cDNA exerts an inhibitory eect on cell growth and cloning eciency. Moreover, all the clones transfected with the RNA-SE6PL cDNA-AS or with the vector alone were tumorigenic, whereas the pRPc and HEY4 cell clones transfected with the RNASE6PL cDNA-S were totally or partially suppressed in tumorigenicity (Tables 2 and  3) . A greater tumorigenic activity was displayed by the clones of SG10G transfected with the RNASE6PL cDNA-S (Table 4) . However, the tumors induced both by HEY4 and SG10G cell clones transfected with the RNASE6PL cDNA showed complete lack of expression of the inserted cDNA, indicating that the exogenous RNASE6PL cDNA was no longer functional in the neoplastic tissue (Tables 3 and 4, Figure  2 ). Finally, while pRPc and SG10G cells showed a normal phenotype in vitro, 63.6% of HEY cell clones and 42.8% of XP12ROSV clones displayed a senescent phenotype.
The analytical examination of the results of the single transfected cell lines indicates that pRPc normal cells and pRPc cells transfected with the empty vector were fully tumorigenic, whereas pRPc cells transfected with the RNASE6PL cDNA-S produced tumors in three out of eight inoculated animals ( Table 2) . Of these three tumors, two completely regressed 30 days after inoculation and the third failed to grow in culture, indicating a limited viability of the tumor cells.
Transfection of HEY cells with the RNASE6PL cDNA-S yielded two classes of clones, since, out of eleven clones expressing the inserted cDNA, seven (63.6%) showed a senescent phenotype in vitro, while four (36.4%) had a normal phenotype. The senescent phenotype gradually appeared and progressed during in vitro propagation of cell clones expressing RNA-SE6PL. Senescence was characterized by large and attened cells, development of cytoplasmic vacuoles and nuclear shrinkage (Figure 3 Radioactive band intensity from each lane was measured by means of a PhosphorImage device and the RNASE6PL expression levels were calculated for each sample following normalization with the signals obtained with the GAPDH control probe Tumor suppressor and senescence-inducing gene at 6q27 F Acquati et al regressed (Table 3) . Of the seven remaining tumors, three, derived from clones SA3, SB2 and SD14 (Table  3) , were tested by RT ± PCR and found to completely lack insert expression (Figure 2a) , thereby con®rming the tumor suppressing activity of the RNASE6PL cDNA. Three clones transfected by RNASE6PL-AS, three clones transfected with the pcDNA3 vector alone and one clone transfected by RNASE6PL-S, but not expressing the inserted cDNA, were tumorigenic (Table  3) . Two clones, SB1 and SC10, showing a normal phenotype in vitro, were suppressed in tumorigenicity ( Table 3 ), suggesting that senescence and suppression of tumorigenicity were induced through two dierent pathways by the RNASE6PL cDNA. Alternatively, the two phenotypes may depend on a quantitative dierence in the expression of the RNASE6PL cDNA. Indeed, dot blot analysis of clones with the senescent and the normal phenotype showed that the senescent clones constantly exhibited a greater expression (twice to three times) of the inserted cDNA, as compared to clones with a normal phenotype which are suppressed in tumorigenicity (data not shown). This suggests that senescence is induced only when the RNase cDNA is expressed in HEY4 cells over a certain threshold, while suppression of tumorigenicity requires only a minimal expression of the insert.
Transfection of SG10G cells with RNASE6PL yielded six clones expressing the inserted cDNA (Table  4) . The in vitro phenotype of these clones was normal and no signs of senescence were detected. Five of the six expressing clones, tested for tumorigenicity, were tumorigenic. However, when tumors, representative of each tumorigenic clone, were analysed by Northern blot hybridization, they were all found to be negative for the expression of the 1.4 Kb RNASE6PL transcript (Figure 2b) . Two SG10G clones transfected with the Clone SA8, which does not express RNASE6PL cDNA, was used as a control in tumorigenicity assays.
e The two tumors completely regressed 30 and 41 days after development. The two tumors induced by clone SA3, the tumor induced by clone SB2 and two tumors induced by clone SD14 were assayed by RT ± PCR for the expression of RNASE6PL cDNA with negative results (see Figure 2A) . ND, not done. NA, not applicable Oncogene Tumor suppressor and senescence-inducing gene at 6q27 F Acquati et al RNASE6PL-AS cDNA, one clone transfected with the vector alone and two clones transfected with RNA-SE6PL-S, but not expressing the transfected cDNA, were fully tumorigenic.
CpG island methylation analysis of the RNASE6PL gene in ovarian cell lines and primary carcinomas
Hypermethylation of normally unmethylated CpG islands in the promoters and 5'¯anking regions of genes, down-regulated in cancers, is associated with loss or reduction of (Jones and Laird, 1999; Baylin and Herman, 2000) . In order to carry out methylation studies, we determined the cap site, the proximal promoter region and more than 1 Kb of 5'-¯anking sequences of the RNASE6PL gene. The region analysed spans the area of greatest CpG density immediately close to the transcription start site of RNASE6PL. Normal ovarian tissue, tumor cell lines and primary cancers were analysed by a methylation-speci®c PCR assay (Herman et al., 1996) which revealed that RNASE6PL is present both in the methylated and unmethylated form in the same sample. No dierences were detected between normal and tumor samples. Moreover, the HEY4, SW626 and OV166 cell lines were treated with the demethylating agent 5-azacytidine to see whether RNASE6PL expression could be increased but no changes were observed. These data suggest that molecular mechanisms other than promoter methylation may control RNASE6PL expression in primary tumors and tumor cell lines.
Discussion
In this study we have investigated the possible role of RNASE6PL as a tumor suppressor gene in ovarian cancer. The gene was cloned at 6q27 Acquati et al., 2000) , a chromosome region often deleted in ovarian tumors and in dierent human neoplasms, such as melanoma, breast cancer, nonHodgkin B-cell lymphoma and several others (Saito et al., 1993; Foulkes et al., 1993; Cooke et al., 1996; Orphanos et al., 1995; Tibiletti et al., 1996; Develee et al., 1991; Theile et al., 1996; Chappel et al., 1997; Queimado et al., 1995; DeSouza et al., 1995; Honchel et al., 1996; Morita et al., 1991; Tahara et al., 1996; Millikin et al., 1991; Gaidano et al., 1992; Hayashi et al., 1990) . RNASE6PL belongs to a group of RNases which are very conserved among species Anderson et al., 1986; Clark et al., 1990; Schneider et al., 1993; Meadoe and Kennell, 1990; McClure et al., 1989; Hime et al., 1995) . These enzymes display dierent functions. However, one of their main eects is regulation of cell growth (McClure et al., 1990) . In particular, a plant RNase, highly homologous to RNASE6PL, is responsible for the expression of gametophytic self-incompatibility in Nicotiana alata (McClure et al., 1990) . This enzyme exerts its action by inhibiting the growth of pollen tubes through degradation of pollen rRNA (McClure et al., 1990) with consequent inhibition of protein synthesis. It may be In parenthesis the mean value of the latency period for the appearance of tumors.
c Clone SB31, which does not express RNASE6PL, and clone S53, which does not contain the insert, were innoculated as controls in tumorigenicity assays. Two tumors induced by clone SA8, the three tumors induced by clones SB13 and SD46, the tumor induced by clone SD43 and one tumor induced by clone SE49 were assayed by Northern blot analysis for the expression of RNASE6PL with negative results (see Figure 2b) . ND, not done. NA, not applicable Figure 2 Lack of human RNASE6PL expression in mouse tumors. Total RNA was puri®ed from several tumor samples obtained following s.c. injection in nude mice of HEY4 (a) and SG10G (b) clones which were previously selected in culture following transfection of an expression vector containing human RNASE6PL cDNA. Total RNA from HEY4-derived tumors (a) was analysed for RNASE6PL expression by RT ± PCR, rather than Northern analysis due to the presence of endogenous RNASE6PL transcripts in this cell line. Lane 1 : 1 kb DNA ladder standard; lanes 2 ± 4: tumor samples representative of HEY4 clones SD14, SA3 and SB2, respectively (see Table 4 conceivable that a similar mechanism could also be operative in the mammalian system, although at present we have no experimental evidence for this eect. On the other hand, it is worth noting that RNases like onconase (Ardelt et al., 1991) and BSRNase (D'Alessio, 1993) are potent inhibitors of cell proliferation and the inhibitory eect is much more evident on actively growing cells, such as immortalized or neoplastic cells (Schein 1997) , lending support to the potential role of these enzymes as tumor suppressors. Indeed, onconase is currently being evaluated for the treatment of mesothelioma in phase III clinical trials . A mutation analysis on 55 ovarian tumors from stage II to stage IV indicated the absence of mutations in the RNASE6PL coding region as well as in the 5' and 3' regulatory regions. Only a few polymorphisms were detected. However, analysis of the same ovarian tumors by Northern blot hybridization showed absence or reduction of RNASE6PL expression in 30% of the samples as compared to normal ovarian tissue. Similarly, expression of the gene was reduced in 75% of ovarian tumor cell lines. In order to shed light on the possible mechanisms responsible for such downregulation we have investigated whether the promoter of the RNASE6PL gene was methylated. Promoter methylation does not seem to account for the reduced RNASE6PL expression as most of the tumors, cell lines and normal ovary display both methylated and unmethylated alleles, without clear dierences between normal and tumor tissues. Most likely other mechanisms are acting in the downregulation of this gene such as local chromatin alterations or mutations in a gene(s) acting upstream of RNASE6PL.
Furthermore, RNASE6PL-transfected ovarian tumor cell lines, inoculated into nude mice, were suppressed in tumorigenicity. All the induced tumors that were analysed resulted completely negative for the expression of the RNASE6PL RNA, con®rming the role of this gene in controlling tumor growth.
Due to its behavior in tumors, RNASE6PL may be de®ned as a class II tumor suppressor gene. Indeed, tumor suppressor genes are distinguished into class I and class II. Class I tumor suppressor genes lose function by deletion, rearrangement or mutation (Haber and Harlow, 1997) ; class II tumor suppressor genes are structurally intact in their sequence, but are underexpressed or unexpressed, due to downregulation or silencing in transcription or translation (Jones and Laird, 1999; Baylin and Herman, 2000) . Loss of expression may in turn depend on alterations aecting an upstream regulatory gene or on epigenetic mechanisms altering the function of the class II gene promoter. It is notable that all the genes which have convincingly been associated with tumor suppressing activity in human ovarian neoplasms belong to class II. Indeed no inactivating mutations in primary tumors and cell lines were reported for GPC3 (Lin et al., 1999) , NOEY2 (Yu et al., 1999) , OVCA1 (Bruening et al., 1999) , SPARC (Mok et al., 1996) DOC-2 , and ZAC/LOT1 genes (Abdollahi et al., 1997; Bilanges et al., 1999) . The GPC3 gene promoter was found to be methylated in several ovarian cancer cell lines (Lin et al., 1999) , whereas the normal allele of the imprinted (Yu et al., 1999) . Thus, with the inclusion of the RNASE6PL gene, these results seem to indicate that epigenetic mechanisms may play an important role in ovarian tumorigenesis, by inactivation or downregulation of tumor suppressor genes.
During the course of these experiments, when RNASE6PL cDNA was transfected into HEY4 and XP12ROSV cells, clear signs of senescence appeared in cell culture. The senescent phenotype was con®rmed by a positive reaction for beta-galactosidase, an enzyme whose expression is speci®cally associated to the process of senescence (Dimri et al., 1995) . Induction of replicative senescence by RNASE6PL is particularly interesting in view of the fact that RNase activity increases in plants during senescence and in human serum in the course of ageing (Schein, 1997; Francesconi et al., 1984) . It is not clear at present why only a proportion of cell clones, both in HEY4 and in XP12ROSV cell cultures, displayed the senescence phenotype. With the single exception of angiogenin, most known RNases (e.g. fungal RNase, BS-RNase, onconase, EDN and the lectin RNases RCE and RJE) are highly selective towards speci®c cell types (D'Alessio, 1993; Schein, 1997) , suggesting that the other cells are somehow protected from the inhibitory eect of RNases on cell growth. Therefore, it is possible that cell clones, not showing senescence after transfection of RNA-SE6PL, derive from single cells developing protective mutations towards the activity of this RNase. Alternatively, the RNASE6PL cDNA may be inactivated by mutation in transfected cell clones displaying a normal phenotype. Induction of senescence by RNASE6PL makes this gene a good candidate for the senescenceinducing gene (SEN6) mapped at 6q27 (Banga et al., 1997) , within the minimal region of LOH detected in ovarian cancer (Saito et al., 1992; Foulkes et al., 1993 , Cooke et al., 1996 Orphanos et al., 1995; Tibiletti et al., 1996 Tibiletti et al., , 1998 or induction of senescence may simply be a phenotypic aspect of the tumor suppressor function displayed by RNASE6PL. The relation of RNASE6PL to SEN6 could be relevant to establish whether an immortalization step is an early event in the process of ovarian tumorigenesis. Indeed, the region where the RNASE6PL gene resides is consistently deleted not only in benign ovarian tumors (Tibiletti et al., 1998) but also in other benign conditions such as parathyroid adenomas (Tahara et al., 1996) and breast benign tumors including ®broadenomas (Tibiletti et al., 2000) . In conclusion, RNASE6PL may represent the candidate gene at 6q27 ful®lling both functions of inducing senescence and of tumor suppressor gene in ovarian cancer.
Materials and methods
Primary tumors, cell lines and culture conditions
Fifty-®ve microdissected primary ovarian tumors, from stage II to stage IV, were selected for mutational and expression analysis in this study. The HEY4 cell line (Buick et al., 1985) , the SG10G cell line (Garzetti et al., 1992) , the Xeroderma Pigmentosum ®broblast cell line XP12ROSV, immortalized by SV40 (Simon et al., 1981) and the ovarian cancer cell lines OV1225, SKOV3, OVCR3, OVRS1000, SW626 and OV166 were cultured in DMEM/F12 medium (GIBCO ± BRL) supplemented with 10% fetal calf serum. pRPcT1/H6c12T (pRPc) cells, derived from a tumor induced by the human/ mouse monochromosomic hybrid pRPcT1/H6, carrying a human chromosome 6 tagged with the neo gene (Gualandri et al., 1994) , were cultured in the same medium in the presence of 300 mg/ml of G418 (Boehringer, Mannheim).
Construction of plasmids and transfection of cells
pRPc cells were cotransfected with the RNASE6PL cDNA inserted in the plasmid pMT89 together with the pGK plasmid carrying the resistance to hygromicin. The HEY4 and SG10G cells, which do not express the RNASE6PL gene (see Results section), were transfected with the RNASE6PL cDNA inserted in the plasmid pcDNA3 (Invitrogen) which contains the neo gene and induces resistance to G418. In both constructs, the RNase cDNA was directed by the cytomegalovirus immediate early promoter. For transfection experiments, the plasmid containing the RNASE6PL cDNA (6 mg per 10 6 cells) was transfected into pRPc, HEY4, SG10G, and XP12ROSV cells with the Superfect reagent (Quiagen), following the manufacturer's instructions. The clones, appearing after approximately two weeks of selection, were harvested by trypsinization with glass cylinders and propagated as mass cultures.
Beta-galactosidase test staining
The test was performed directly in the culture¯asks according to Dimri et al. (1995) .
Thymidine incorporation test
Two610
4 cells were cultured on glass dishes in 24-well plates in the presence of [ 3 H]thymidine (1 mCi/ml). After 72 h, cells were extensively washed in PBS, dishes were recovered from the wells, resuspended in 1 ml of INSTA-GEL II PLUS (Packard) and the radioactivity was measured in a Packard TRI-CARB 4530 beta counter.
Tumorigenicity assays
To test for tumorigenicity in nude mice, cells were trypsinized, harvested and washed twice. Five610 4 pRPc cells, 1610 5 HEY4 cells and 2610 6 SG10G cells were suspended in 0.1 ml of serum-free medium and inoculated s.c. into 3-week-old nude BALB/c mice. Animals were examined for tumor formation for up to 6 months. After that time, if tumors had not appeared, the cells were considered suppressed in tumorigenicity.
PCR and RT ± PCR
Cells from each clone were harvested from 18 mm wells and suspended in 0.5 ml of culture medium. Twenty per cent of the suspension was directly used for PCR to con®rm the presence of the transfected cDNA, while the remaining 80% was used for RNA extraction followed by RT ± PCR. For PCR reaction, the cell pellet was treated at 558C for 1 h in 10 mM Tris pH 8.3, 1.25 mM MgCl 2 , 0.01% gelatine, 0.45% Tween 20, 0.45% NP-40, 10 mg/ml proteinase K. After
Tumor suppressor and senescence-inducing gene at 6q27 F Acquati et al inactivation of proteinase K for 10 min at 958C, the reaction mixture was briefely centrifuged and 1 ml of the cell lysate was used for PCR analysis with T7 and Sp6 primers, designed on the arms of the expression vector. The conditions of the reaction were: 948C for 30 s, 558C for 30 s, 728C for 60 s, 30 cycles. For RT ± PCR analysis, total RNA was extracted with the RNAwiz reagent (Ambion) following the manufacturer's instructions and reverse transcription was carried out using the cDNA Synthesis System (Gibco ± BRL). GAPDH ampli®cation was performed to control cDNA synthesis. To discriminate from the endogenous RNASE6PL transcript, the expression of the transfected cDNA was tested using the T7 primer from the vector and a speci®c primer for the RNASE6PL cDNA (5'-TTGGGCATCAATGCTTGG-3'). cDNA ampli®cation was then carried out as described for the PCR reaction.
RNASE6PL methylation status analysis by methylation specific PCR (MSP)
MSP was carried out as described by Herman et al. (1996) . Two mg of sodium bisul®te-treated genomic DNA from the samples of interest was puri®ed and used for MSP analysis using the following primers: 44bis-MetA: 5' TTTGCGT-GGCGAAGGAACGTAGTCGTT-3' and 44new-MetB: 5'-TACAACAACGACCACCGAATACGCCCG-3' (to amplify methylated DNA); 44bis-UnmetA: 5'-GGTGTTTGTG-TGGTGAAGGAATGTAGTTGTT-3', and 44new-UnmetB: 5'-TCCACTACAACAACAACCACCAAATACACCC-3' (to amplify unmethylated DNA) PCR conditions were as follows: 948C 2 min, then 40 cycles at 928C 30 s, 618C 30 s, 728C 60 s with primers 44bis-MetA and 44new-MetB; :948C 2 min, then 40 cycles at 928C 30 s, 598C 30 s, 728C 60 s with primers 44bis-UnmetA and 44new-UnmetB. As a control for the speci®city of the primers, the same PCR reactions were carried out using DNA which had not been treated with sodium bisul®te.
PCR-single-strand conformation polymorphism (SSCP)
DNA was prepared from 55 tumors and from the ovarian carcinoma cell line HEY4, using standard phenol-chlorophorm extraction. Primer pairs were designed in intronic regions¯anking each exon and in the 5' and 3' untranslated regions of the RNASE6PL gene. Every single exon of the RNASE6PL gene was PCR ampli®ed (primer sequences and PCR conditions are available on request). SSCP analysis was performed on tumor DNAs as previously described (Varesco et al., 1993) .
